Literature DB >> 24390859

Unplanned revisits and readmissions after ambulatory sinonasal surgery.

Neil Bhattacharyya1.   

Abstract

OBJECTIVES/HYPOTHESIS: Determine rates and reasons for revisits after adult ambulatory sinonasal surgery. STUDY
DESIGN: Cross-sectional analysis of multi-state ambulatory surgery and hospital databases.
METHODS: Ambulatory adult sinonasal procedures were extracted from the State Ambulatory Surgery Databases for New York, Florida, Iowa, and California for 2010. Cases were linked to the State Emergency Department Databases and the State Inpatient Databases for visit encounters occurring 0 to 14 days after the procedure. The number of revisits (including readmissions) was determined as well as the reason for revisit. The overall rate of and intervention rate for postprocedural bleeding were determined.
RESULTS: A total of 35,678 ambulatory sinonasal cases were extracted (mean age, 47.5 years). Overall, 5.0% of patients had a revisit after surgery (18.9% revisited the ambulatory surgery center, 67.0% the emergency department, and 14.1% to inpatient admission). The primary diagnoses at the first revisit were bleeding (23.0%), acute pain (3.7%), and fever/dehydration (3.8%). Overall, 0.8% of patients incurred a second revisit. Among all cases, 1.2% and 0.3% presented with a bleeding diagnosis at a first and second revisit, respectively. Among revisits, 1.0% and 17.9% underwent a procedure to control bleeding at the first and second revisits, respectively. Three deaths were noted for an overall 14-day mortality rate of 0.0084%.
CONCLUSION: There is a nonnegligible revisit rate after ambulatory sinonasal surgery. The most common reasons for revisit include bleeding, but also acute pain and fever/dehydration. These particular complications should be targeted for prevention to reduce postoperative revisit rates.
© 2014 The American Laryngological, Rhinological and Otological Society, Inc.

Entities:  

Keywords:  Sinus surgery; complications; dehydration; postoperative hemorrhage; readmission; septoplasty

Mesh:

Year:  2014        PMID: 24390859     DOI: 10.1002/lary.24584

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  6 in total

Review 1.  Comprehensive review on endonasal endoscopic sinus surgery.

Authors:  Rainer K Weber; Werner Hosemann
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2015-12-22

2.  Outcomes of endoscopic ethmoidectomy performed on a day-case basis: a prospective bi-centric study.

Authors:  N Oker; V Dupuch; P Herman; N Leclerc; P Vironneau; H Dang; J Majer; R Pastourel; Y Pavier; J-P Blancal; N Saroul; T Mom; R Kania; E Vicaut; L Gilain; B Verillaud
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-08-17       Impact factor: 2.503

3.  Evaluating Surgeon-Specific Performance for Endoscopic Sinus Surgery.

Authors:  Luke Rudmik; Yuan Xu; Jeremiah A Alt; Adam Deconde; Timothy L Smith; Rodney J Schlosser; Hude Quan; Zachary M Soler
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2017-09-01       Impact factor: 6.223

4.  Analgesic Effects of Intravenous Acetaminophen vs Placebo for Endoscopic Sinus Surgery and Postoperative Pain: A Randomized Clinical Trial.

Authors:  Matthew A Tyler; Kent Lam; Faramarz Ashoori; Chunyan Cai; Joshua J Kain; Samer Fakhri; Martin J Citardi; Davide Cattano; Amber Luong
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2017-08-01       Impact factor: 6.223

5.  Pain and haemorrhage are the most common reasons for emergency department use and hospital admission in adults following ambulatory surgery: results of a population-based cohort study.

Authors:  Monakshi Sawhney; David H Goldstein; Xuejiao Wei; Genevieve C Pare; Louie Wang; Elizabeth G VanDenKerkhof
Journal:  Perioper Med (Lond)       Date:  2020-08-19

6.  Thirty-Day Hospital Revisit Rates and Factors Associated With Revisits in Patients Undergoing Septorhinoplasty.

Authors:  Emily Spataro; Gregory H Branham; Dorina Kallogjeri; Jay F Piccirillo; Shaun C Desai
Journal:  JAMA Facial Plast Surg       Date:  2016-12-01       Impact factor: 4.611

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.